How Does CAR-T Cell Therapy for Follicular Lymphoma Work? What the Evidence Shows

Follicular lymphoma (FL) is usually a slow-moving cancer, but for the roughly one-fifth to one-third of patients whose disease keeps returning despite multiple rounds of chemoimmunotherapy, options narrow and outcomes worsen with each relapse. Two CD19-directed CAR-T cell therapies — axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi) — now carry FDA accelerated approval for relapsed or refractory FL after at least two prior lines of therapy, and the response rates reported in their pivotal trials are among the highest seen anywhere in the CAR-T field. This article explains how these therapies work, what the trial evidence actually shows, and where real caveats — CRS, neurotoxicity, accelerated-approval status, cost, and access — still apply.

What Follicular Lymphoma Is, and Why CAR-T Entered the Picture

Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin lymphoma, with an incidence of about 2.4 new cases per 100,000 people per year in the U.S. and a 5-year relative survival rate of 88.9%, according to the National Cancer Institute's SEER program. Most patients respond well to first-line chemoimmunotherapy, but FL is generally considered incurable with standard treatment, and it tends to relapse repeatedly. Each subsequent relapse is typically harder to treat, and a subset of patients — those who progress within 24 months of first-line therapy, or who become refractory to multiple regimens — face a genuinely difficult prognosis with older options like chemotherapy combinations, targeted agents, or stem cell transplant. It was this late-line, heavily pretreated population that CAR-T trials targeted.

How the Approved CAR-T Products Work

Both approved products use the same core mechanism: a patient's own T cells are collected by apheresis, genetically engineered outside the body to express a chimeric antigen receptor (CAR) targeting CD19 — a protein found on the surface of B cells, including the malignant B cells that make up follicular lymphoma — and then infused back after a short course of lymphodepleting chemotherapy. Once reinfused, the CAR-T cells recognize and bind CD19 directly, triggering the T cell to kill the target cell without needing conventional antigen presentation. This is a one-time, individualized manufacturing process (typically several weeks from apheresis to infusion), not a chronic medication.

What the Pivotal Trial Data Actually Show

Axicabtagene ciloleucel (Yescarta) received FDA accelerated approval on March 5, 2021, for adults with relapsed or refractory FL after two or more lines of systemic therapy, based on the single-arm ZUMA-5 trial. In the primary efficacy population (n=81), the objective response rate was 91%, with 60% of patients achieving a complete response. A five-year follow-up analysis of ZUMA-5 (published in the Journal of Clinical Oncology in 2025, FL cohort n=127) reported an ORR of 90%, a CR rate of 75%, a median duration of response of 60.4 months, and 50.4% of patients progression-free at five years — figures that, for a heavily relapsed lymphoma population, are genuinely notable and support the drug's durability, even as "five-year" data still represents one cohort from one trial rather than a guarantee for any individual patient.

Lisocabtagene maraleucel (Breyanzi) received accelerated approval on May 15, 2024, for the same indication (two or more prior lines), based on the phase 2 TRANSCEND FL trial. In the FDA's approval-summary primary efficacy population (n=94), the independent-review-committee-assessed ORR was 95.7%, with a 73.4% complete response rate; at a median follow-up of roughly 16.8 months, median duration of response had not been reached, with an estimated 80%+ of responses ongoing at one year.

These are single-arm trials without a randomized comparator arm, which limits direct efficacy comparisons between the two products and against non-CAR-T options — cross-trial comparisons should be read cautiously.

Safety: CRS and Neurotoxicity Are Real and Product-Specific

Both products carry boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity, including fatal or life-threatening reactions, and — as a CAR-T class-wide warning — for the rare possibility of secondary T-cell malignancies following treatment. The magnitude of risk differs between the two products in their respective trials. In ZUMA-5 (axi-cel), CRS of any grade occurred in 84% of the indolent NHL population, with grade 3 or higher CRS in 8%; neurologic toxicities occurred in 77%, with grade 3 or higher in 21%. In TRANSCEND FL (liso-cel), CRS occurred in 58% of patients (grade 3 or higher in about 1%), and neurologic events occurred in about 15% (grade 3 or higher in about 2%) — a lower-toxicity profile in this trial population, though again, these are separate single-arm studies, not a head-to-head comparison.

Who Is — and Isn't — a Candidate

Both therapies are approved only after at least two prior systemic therapies have failed; they are not first- or second-line options. Candidacy also depends on practical factors that patients often underestimate: treatment requires apheresis and several weeks of manufacturing lead time, infusion and monitoring at a certified CAR-T treatment center (there are a limited number nationally), adequate organ function, and typically a caregiver and proximity to the treatment center for weeks after infusion because of the CRS/neurotoxicity risk window. Patients with uncontrolled infections, certain CNS involvement, or poor performance status may be excluded. Cost and insurance authorization are also significant real-world barriers, as CAR-T list prices run into the hundreds of thousands of dollars before accounting for the hospitalization and monitoring required around infusion.

What's Still Uncertain

Both approvals are accelerated approvals, granted on response-rate data with confirmatory trials and longer follow-up required to verify lasting clinical benefit, including overall survival. Relapse after CAR-T still occurs in a meaningful minority of patients, and it is not yet fully clear how durability compares with newer options like bispecific antibodies, or how sequencing CAR-T earlier versus later in the treatment course affects long-term outcomes. Longer-term monitoring for rare secondary malignancies, and real-world outcomes outside the controlled trial setting, remain areas actively being tracked.

Bottom Line

For patients with follicular lymphoma that has relapsed after multiple prior treatments, CD19-directed CAR-T therapy — axicabtagene ciloleucel and lisocabtagene maraleucel — offers response rates (roughly 90–96% overall, 60–75%+ complete response in pivotal trials) that are among the strongest reported for any CAR-T indication, with axi-cel's five-year data suggesting many responses are durable. That is a genuinely encouraging result for a population with historically limited options. It comes, however, with real and product-specific risks of cytokine release syndrome and neurotoxicity, accelerated-approval status pending longer-term confirmation, restriction to later treatment lines, and substantial cost and access barriers. Patients considering CAR-T for FL should discuss individual eligibility, expected toxicity, and realistic long-term expectations with a certified treatment center.